company background image
ABEO logo

Abeona Therapeutics NasdaqCM:ABEO Stock Report

Last Price

US$5.70

Market Cap

US$247.8m

7D

-3.2%

1Y

14.7%

Updated

22 Dec, 2024

Data

Company Financials +

Abeona Therapeutics Inc.

NasdaqCM:ABEO Stock Report

Market Cap: US$247.8m

ABEO Stock Overview

A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. More details

ABEO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Abeona Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Abeona Therapeutics
Historical stock prices
Current Share PriceUS$5.70
52 Week HighUS$9.01
52 Week LowUS$3.05
Beta1.44
1 Month Change-4.68%
3 Month Change-2.73%
1 Year Change14.69%
3 Year Change-36.91%
5 Year Change-93.32%
Change since IPO-100.00%

Recent News & Updates

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Sep 23
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Recent updates

Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

Sep 23
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

May 01
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Jan 04
We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate

Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Aug 16
Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation

Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Mar 31
Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?

Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value

Oct 19

Abeona Therapeutics stock continues recent strong run, shares rise ~10%

Oct 04

Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M

Aug 11

Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement

Jul 20

Abeona crashes 21% as reverse stock split takes effect

Jul 05

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Mar 02
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely

Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Aug 17
Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money

Abeona Therapeutics shares rise after letter to stockholders

May 26

Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Apr 28
Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt

Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

Feb 21
Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)

How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

Jan 19
How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?

What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Dec 15
What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?

Shareholder Returns

ABEOUS BiotechsUS Market
7D-3.2%-3.6%-2.4%
1Y14.7%-2.6%23.4%

Return vs Industry: ABEO exceeded the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: ABEO underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is ABEO's price volatile compared to industry and market?
ABEO volatility
ABEO Average Weekly Movement5.4%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ABEO has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ABEO's weekly volatility has decreased from 12% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a84Vish Seshadriwww.abeonatherapeutics.com

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.

Abeona Therapeutics Inc. Fundamentals Summary

How do Abeona Therapeutics's earnings and revenue compare to its market cap?
ABEO fundamental statistics
Market capUS$247.78m
Earnings (TTM)-US$71.03m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABEO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$31.40m
Gross Profit-US$31.40m
Other ExpensesUS$39.63m
Earnings-US$71.03m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.63
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio40.7%

How did ABEO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Abeona Therapeutics Inc. is covered by 23 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
George ZavoicoB. Riley Securities, Inc.
Elemer PirosCantor Fitzgerald & Co.